The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
22-Jul-97
$1.7 billion
Target:
Cigarrera La Moderna
Acquiror:
B.A.T. Industries Plc
, subsidiary of Empresas La Moderna Advised Empresas La Moderna on the sale of its subsidiary Cigarrera La Moderna, Mexico’s largest cigarette producer, for a combination of cash and redeemable notes
15-Feb-00
$555 million
Target:
Seguros Comercial América
Acquiror:
ING Groep N.V.
, S.A. de C.V. (stake owned by Savia S.A. de C.V.)
Advised Savia on the sale of a minority stake in Seguros Comercial América, the largest Mexican insurance company, to ING Groep.
06-May-02
$1.4 billion
Target:
Pegaso Telecomunicaciones
Acquiror:
Telefonica Moviles S.A.
Advised Pegaso, Mexico’s No. 2 wireless provider, on its financial restructuring and subsequent sale of 65% stake to Telefonica
06-May-02
$1.4 billion
Target:
Pegaso Telecommunications
Advised Pegaso, Mexico’s No. 2 wireless provider, on its financial restructuring and subsequent sale of 65% stake to Telefonica for $1.36 billion
19-Feb-03
$110 million
Target:
AT&T Latin America
Advised AT&T Latin America on the restructuring and sale of its South American subsidiaries in Argentina, Brazil, Chile, Colombia and Peru to Telefonos de Mexico for $206.7 million. Also advised ATTLA on the resolution of it US Chapter 11 proceedings
03-Apr-06
$3.7 billion
Target:
Verizon Communications Inc.
Acquiror:
América Móvil and Telmex
(various assets)
Provided independent valuation services in connection with the acquisition by América Móvil and Telmex of a 100% stake in Verizon Dominicana, an approximate 52% stake in Telecomunicaciones de Puerto Rico and an approximate 28.5% stake in Compania Anónima Nacional Teléfonos de Venezuela
04-Aug-06
$290 million
Target:
Republic Companies Group, Inc.
Acquiror:
Delek Capital Ltd.
Advised Republic Companies Group, Inc., a regional provider of personal and commercial property and casualty insurance products
03-Mar-10
$NA
Target:
Puerta Mexico Transportation Facility
Acquiror:
Kansas City Southern
Advised Ports America, Inc., a portfolio company of Highstar Capital, on its sale of Puerta Mexico, a state-of-the-art customs-clearing intermodal transportation facility located in the Mexico City market
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
04-Nov-10
~$370 million
Target:
J. Malucelli Participacao em Seguros E Resseguros S.A
Acquiror:
The Travelers Companies, Inc.
Advised Travelers, the largest listed property and casualty insurance company in the U.S., on the acquisition of a ~43% stake in J. Malucelli Participacao em Seguros E Resseguros, the leading surety insurance company in Brazil, through the issue of new common shares (with an option to increase to 49.9% within 18 months)
21-Mar-11
$NA
Target:
Close Brothers Cayman Limited
Acquiror:
Intertrust Group Holdings SA
Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA
11-Apr-11
~$198 million
Target:
HSBC Afore (subsidiary of HSBC Holdings Plc)
Acquiror:
Principal Financial Group, Inc.
Advised Principal Financial Group, Inc., a leading asset accumulation, asset management and retirement services franchise in the United States and abroad on its acquisition of HSBC Afore, HSBC’s pension business in Mexico
10-Aug-11
$65 million
Target:
Grupo Aeromexico S.A. de C.V
Acquiror:
Delta Air Lines, Inc.
Advised Delta Air Lines, Inc. in connection with its strategic minority investment in Grupo Aeromexico S.A. de C.V
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
22-Dec-15
$NA
Target:
Hortifruti
Acquiror:
Partners Group
Advised Hortifruti, Brazil's number one premium retailer of healthy food, on the sale of a significant minority stake to Partners Group, a global private markets investment manager
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise
26-Feb-16
$NA
Target:
Policard
Acquiror:
Groupe Up
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
22-Apr-16
$NA
Target:
Elavon do Brasil
Acquiror:
Stone Pagamentos
Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.
10-May-16
$NA
Target:
Brasil/CT
Acquiror:
Invest Tech
Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products